We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+20.89%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$6.13B
AUM Growth
+$563M
Cap. Flow
-$172M
Cap. Flow %
-2.8%
Top 10 Hldgs %
24.72%
Holding
175
New
20
Increased
65
Reduced
40
Closed
23

Top Buys

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$59.7M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$54.7M
3
LXEO icon
Lexeo Therapeutics
LXEO
+$37.3M
4
MNDY icon
monday.com
MNDY
+$32.9M
5
XMTR icon
Xometry
XMTR
+$28.5M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$79.8M
2
EXAS
Exact Sciences
EXAS
+$51.4M
3
SHLS icon
Shoals Technologies Group
SHLS
+$42.6M
4
ASND icon
Ascendis Pharma A/S
ASND
+$39.3M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$39.2M

Sector Composition

Rank Sector Weight
1 Healthcare 39.38%
2 Technology 24.68%
3 Industrials 16.87%
4 Consumer Discretionary 8.76%
5 Communication Services 2.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
126
Ironwood Pharmaceuticals
IRWD
$614M
$8.47M 0.14%
+740,554
New +$7.33M
SRE icon
127
Sempra
SRE
$58.6B
$8.4M 0.14%
+112,340
New +$8.04M
EQIX icon
128
Equinix
EQIX
$103B
$7.67M 0.13%
9,528
-1,078
-10% -$828K
INCY icon
129
Incyte
INCY
$24.9B
$7.63M 0.12%
+121,508
New +$6.87M
TGTX icon
130
TG Therapeutics
TGTX
$8.19B
$7.51M 0.12%
+439,474
New +$5.11M
BEAM icon
131
Beam Therapeutics
BEAM
$2.73B
$7.11M 0.12%
261,360
– –
PNFP icon
132
Pinnacle Financial Partners Inc
PNFP
$15.8B
$7.05M 0.12%
+80,841
New +$5.86M
CBT icon
133
Cabot Corp
CBT
$4.55B
$6.92M 0.11%
+82,861
New +$6.16M
RCUS icon
134
Arcus Biosciences
RCUS
$3.55B
$4.58M 0.07%
240,000
– –
PCOR icon
135
Procore
PCOR
$8.12B
$3.3M 0.05%
+47,702
New +$2.94M
INTA icon
136
Intapp
INTA
$2.47B
$3.27M 0.05%
86,036
+53
+0.1% +$1.95K
YARW
137
Yarrow Bioscience, Inc. Common Stock
YARW
$22M
$3.25M 0.05%
+27,887
New +$4.35M
AIP icon
138
Arteris
AIP
$1.35B
$2.35M 0.04%
399,023
– –
LIN icon
139
Linde
LIN
$235B
$1.88M 0.03%
4,574
+2,735
+149% +$1.08M
SPGI icon
140
S&P Global
SPGI
$122B
$1.85M 0.03%
4,208
+1,933
+85% +$763K
TSBX
141
DELISTED
Turnstone Biologics
TSBX
$1.8M 0.03%
708,317
– –
NOW icon
142
ServiceNow
NOW
$114B
$1.4M 0.02%
9,885
+2,630
+36% +$331K
INTU icon
143
Intuit
INTU
$86.3B
$1.23M 0.02%
+1,974
New +$1.09M
SNV
144
DELISTED
Synovus
SNV
$968K 0.02%
+25,714
New +$786K
TSM icon
145
TSMC
TSM
$2.09T
$913K 0.01%
8,775
+1,926
+28% +$184K
NVDA icon
146
NVIDIA
NVDA
$4.72T
$774K 0.01%
15,620
+4,160
+36% +$193K
SHOP icon
147
Shopify
SHOP
$159B
$697K 0.01%
8,951
-4,419
-33% -$282K
ZTS icon
148
Zoetis
ZTS
$31.9B
$622K 0.01%
3,153
+917
+41% +$162K
EW icon
149
Edwards Lifesciences
EW
$50B
$512K 0.01%
6,709
-3,085
-31% -$215K
ALGN icon
150
Align Technology
ALGN
$12.4B
$307K 0.01%
1,121
-804
-42% -$191K
3 4 5
6
7

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q4 2023 Portfolio in Review

As of Q4 2023, Eventide Asset Management held 175 positions worth $6.13B, up 10% from $5.56B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Eventide Asset Management's Q4 2023 filing shows 20 new, 65 increased, 40 reduced and 23 closed positions. Its largest new stake was Lexeo Therapeutics: 3,002,831 shares worth $40.3M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $79.8M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 41% a quarter earlier, followed by Technology and Industrials.

  • Eventide Asset Management's largest Q4 2023 buy was Lexeo Therapeutics: 3,002,831 shares worth $40.3M.
  • Eventide Asset Management added most to Celldex Therapeutics in Q4 2023, an estimated $59.7M increase.
  • Eventide Asset Management's biggest Q4 2023 reduction was Exact Sciences, cutting an estimated $51.4M.
  • Eventide Asset Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $79.8M.
  • Eventide Asset Management's ten largest holdings make up 25% of its $6.13B portfolio in Q4 2023.
  • Eventide Asset Management opened 20 new positions and closed 23 in Q4 2023.
  • Eventide Asset Management's portfolio value rose 10% quarter-over-quarter to $6.13B.

Based on Eventide Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.